Solutions Through Immunology

Advancing Vaccines and BioTherapeutics

Our GMP, Your IND

Advancing Vaccines and BioTherapeutics

Breakthroughs Delivered

Advancing Vaccines and BioTherapeutics

About ABL

ABL has been nominated for two Vaccine Industry Excellence (ViE) awards:

Best Contract Research Organization

Best Contract Manufacturing Organization.

Click here to cast your vote!

Spotlight

ABL, Inc. Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID).

Read More

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

ABL has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine.  The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority (BARDA) and represents a critical response to the developing global risk of Zika infections.

Read More

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

ABL is pleased to announce the award of a contract for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention.” ABL will provide the Division of AIDS in the National Institute of Allergy and Infectious Disease with a comprehensive suite of preclinical product development services for candidate non-vaccine biomedical prevention products to prevent sexual HIV transmission.

Read More

ABL, Inc. Acquires GMP Virus Manufacturing Facility in France

With this acquisition, ABL establishes itself as a premier global CMO for the production of virus-based therapies and vaccines with the ability to significantly increase client responsiveness and schedule flexibility. The site in Strasbourg, France will be operated by ABL’s wholly owned subsidiary, ABL Europe S.A.S. to produce live virus-based gene therapies, oncolytic therapies, and vaccines on a contract basis for clinical and commercial supply.

Read More